Paolo Preziosa

List of Publications by Year in Descending Order

92 papers	2,114 citations	23 h-index	44 g-index
112 ext. papers	2,970 ext. citations	6.9 avg, IF	5.17 L-index

#	Paper	IF	Citations
92	A Deep Learning Approach to Predicting Disease Progression in Multiple Sclerosis Using Magnetic Resonance Imaging.. *Investigative Radiology*, **2022**,	10.1	2
91	Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.. *Neurology: Neuroimmunology and NeuroInflammation*, **2022**, 9,	9.1	6
90	Divergent time-varying connectivity of thalamic sub-regions characterizes clinical phenotypes and cognitive status in multiple sclerosis.. *Molecular Psychiatry*, **2022**,	15.1	1
89	Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis.. *Journal of Neurology*, **2022**, 1	5.5	1
88	Pediatric multiple sclerosis: developments in timely diagnosis and prognostication.. *Expert Review of Neurotherapeutics*, **2022**, 1-11	4.3	0
87	Amyloid-p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's disease.. *Brain Communications*, **2021**, 3, fcab281	4.5	0
86	MRI of Transcallosal White Matter Helps to Predict Motor Impairment in Multiple Sclerosis. *Radiology*, **2021**, 210922	20.5	0
85	Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity. *Journal of Neurology*, **2021**, 1	5.5	2
84	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study. *Neurology*, **2021**,	6.5	4
83	Quantitative MRI adds to neuropsychiatric lupus diagnostics. *Rheumatology*, **2021**, 60, 3278-3288	3.9	1
82	Resting state network functional connectivity abnormalities in systemic lupus erythematosus: correlations with neuropsychiatric impairment. *Molecular Psychiatry*, **2021**, 26, 3634-3645	15.1	8
81	Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 1520-1532	5	6
80	COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. *Journal of Neurology*, **2021**, 268, 2697-2699	5.5	6
79	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. *JAMA Neurology*, **2021**, 78, 351-364	17.2	11
78	Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?. *Journal of Neurology*, **2021**, 268, 3975-3979	5.5	1
77	Central vein sign and iron rim in multiple sclerosis: ready for clinical use?. *Current Opinion in Neurology*, **2021**, 34, 505-513	7.1	4
76	Unraveling the substrates of cognitive impairment in multiple sclerosis: A multiparametric structural and functional magnetic resonance imaging study. *European Journal of Neurology*, **2021**, 28, 3749-3759	6	1

75	Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study. *Multiple Sclerosis Journal*, **2021**, 27, 380-390	5	6
74	Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging. *Multiple Sclerosis Journal*, **2021**, 27, 818-826	5	9
73	Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 139-146	5	8
72	Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study. *Neurotherapeutics*, **2021**, 18, 878-888	6.4	2
71	Effect of cognitive reserve on structural and functional MRI measures in healthy subjects: a multiparametric assessment. *Journal of Neurology*, **2021**, 268, 1780-1791	5.5	3
70	Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 790-792	5.5	6
69	Functional and structural MRI correlates of executive functions in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 13524585211033184	5	1
68	Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. *Journal of Neurology*, **2021**, 1	5.5	9
67	Human Functional MRI. *Neuromethods*, **2021**, 213-236	0.4	
66	Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. *Neurology*, **2021**, 96, e1561-e1573	6.5	5
65	Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?. *Journal of Neurology*, **2021**, 268, 717-723	5.5	5
64	Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability.. *Brain*, **2021**,	11.2	4
63	Distribution of pathological hallmarks and association with post-mortem MRI cortical thickness in typical and atypical Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e042784	1.2	
62	COVID-19 will change MS care forever - No. *Multiple Sclerosis Journal*, **2020**, 26, 1149-1151	5	5
61	Clinical Relevance of Multiparametric MRI Assessment of Cervical Cord Damage in Multiple Sclerosis. *Radiology*, **2020**, 296, 605-615	20.5	12
60	COVID-19 in teriflunomide-treated patients with multiple sclerosis. *Journal of Neurology*, **2020**, 267, 2790-2796	5.5	37
59	Identifying Progression in Multiple Sclerosis: New Perspectives. *Annals of Neurology*, **2020**, 88, 438-452	9.4	30
58	What role should spinal cord MRI take in the future of multiple sclerosis surveillance?. *Expert Review of Neurotherapeutics*, **2020**, 20, 783-797	4.3	6

57	Two-year regional grey and white matter volume changes with natalizumab and fingolimod. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 493-502	5.5	6
56	Cognitive impairment in benign multiple sclerosis: a multiparametric structural and functional MRI study. *Journal of Neurology*, **2020**, 267, 3508-3517	5.5	6
55	Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring. *Expert Review of Neurotherapeutics*, **2020**, 20, 747-769	4.3	6
54	Fatigue in multiple sclerosis patients with different clinical phenotypes: a clinical and magnetic resonance imaging study. *European Journal of Neurology*, **2020**, 27, 2549-2560	6	5
53	Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study. *Multiple Sclerosis Journal*, **2020**, 26, 233-244	5	9
52	Structural and functional brain connectomes in patients with systemic lupus erythematosus. *European Journal of Neurology*, **2020**, 27, 113-e2	6	12
51	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis. *Neurotherapeutics*, **2020**, 17, 208-217	6.4	16
50	Lifespan normative data on rates of brain volume changes. *Neurobiology of Aging*, **2019**, 81, 30-37	5.6	24
49	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. *Brain*, **2019**, 142, 1858-1875	11.2	150
48	Functional and structural plasticity following action observation training in multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 1472-1487	5	17
47	Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders. *Multiple Sclerosis Journal*, **2019**, 25, 968-979	5	8
46	MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis. *Journal of Neurology*, **2019**, 266, 2848-2858	5.5	7
45	Axonal degeneration as substrate of fractional anisotropy abnormalities in multiple sclerosis cortex. *Brain*, **2019**, 142, 1921-1937	11.2	16
44	Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. *Neurology*, **2019**, 93, e1852-e1866	6.5	22
43	PET is necessary to make the next step forward in understanding MS pathophysiology - No. *Multiple Sclerosis Journal*, **2019**, 25, 1088-1090	5	1
42	Can MRI be used as a proxy for ? A case study. *Brain Communications*, **2019**, 1, fcz030	4.5	8
41	Association between pathological and MRI findings in multiple sclerosis. *Lancet Neurology, The*, **2019**, 18, 198-210	24.1	86
40	Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives. *Expert Review of Neurotherapeutics*, **2019** , 19, 835-866	4.3	12

39	Brain mapping in multiple sclerosis: Lessons learned about the human brain. *NeuroImage*, **2019**, 190, 32-45	7.9	33
38	Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 204-216	5	16
37	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. *Nature Reviews Neurology*, **2018**, 14, 199-213	15	95
36	Cervical Cord T1-weighted Hypointense Lesions at MR Imaging in Multiple Sclerosis: Relationship to Cord Atrophy and Disability. *Radiology*, **2018**, 288, 234-244	20.5	28
35	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. *Lancet Neurology, The*, **2018**, 17, 133-142	24.1	66
34	Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 316-318	5.5	14
33	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. *Multiple Sclerosis and Related Disorders*, **2018**, 25, 73-76	4	3
32	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. *Acta Neurologica Scandinavica*, **2018**, 138, 447-453	3.8	2
31	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. *Journal of the Neurological Sciences*, **2018**, 384, 58-60	3.2	1
30	Multiple sclerosis. *Nature Reviews Disease Primers*, **2018**, 4, 43	51.1	372
29	MRI in multiple sclerosis: what is changing?. *Current Opinion in Neurology*, **2018**, 31, 386-395	7.1	13
28	DT MRI microstructural cortical lesion damage does not explain cognitive impairment in MS. *Multiple Sclerosis Journal*, **2017**, 23, 1918-1928	5	7
27	The Italian Neuroimaging Network Initiative (INNI): enabling the use of advanced MRI techniques in patients with MS. *Neurological Sciences*, **2017**, 38, 1029-1038	3.5	6
26	Microstructural MR Imaging Techniques in Multiple Sclerosis. *Neuroimaging Clinics of North America*, **2017**, 27, 313-333	3	23
25	Moyamoya disease mimicking the first attack of multiple sclerosis. *Journal of Neurology*, **2017**, 264, 1005-1007	5.5	2
24	Progression of regional atrophy in the left hemisphere contributes to clinical and cognitive deterioration in multiple sclerosis: A 5-year study. *Human Brain Mapping*, **2017**, 38, 5648-5665	5.9	23
23	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. *Neurological Sciences*, **2017**, 38, 361-364	3.5	5
22	Action observation training modifies brain gray matter structure in healthy adult individuals. *Brain Imaging and Behavior*, **2017**, 11, 1343-1352	4.1	6

21	Optic neuritis in multiple sclerosis: Looking from a patient's eyes. *Neurology*, **2016**, 87, 338-9	6.5	0
20	A Semiautomatic Method for Multiple Sclerosis Lesion Segmentation on Dual-Echo MR Imaging: Application in a Multicenter Context. *American Journal of Neuroradiology*, **2016**, 37, 2043-2049	4.4	4
19	Multiple sclerosis. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2016**, 135, 399-423	3	7
18	Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A Multicenter Study. *Human Brain Mapping*, **2016**, 37, 1627-44	5.9	65
17	Clinically Isolated Syndrome Suggestive of Multiple Sclerosis: Dynamic Patterns of Gray and White Matter Changes-A 2-year MR Imaging Study. *Radiology*, **2016**, 278, 841-53	20.5	26
16	The Role of DTI in Multiple Sclerosis and Other Demyelinating Conditions **2016**, 331-341		1
15	Estimating Brain Lesion Volume Change in Multiple Sclerosis by Subtraction of Magnetic Resonance Images. *Journal of Neuroimaging*, **2016**, 26, 395-402	2.8	7
14	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. *Journal of the Neurological Sciences*, **2016**, 361, 184-6	3.2	2
13	Brain reserve against physical disability progression over 5 years in multiple sclerosis. *Neurology*, **2016**, 86, 2006-9	6.5	21
12	Subacute visual loss and bilateral fixed mydriasis: an atypical case of giant cell arteritis. *Neurological Sciences*, **2014**, 35, 1309-10	3.5	2
11	Relationship between damage to the cerebellar peduncles and clinical disability in multiple sclerosis. *Radiology*, **2014**, 271, 822-30	20.5	38
10	Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?. *Current Opinion in Neurology*, **2014**, 27, 290-9	7.1	52
9	Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 192-201	5	76
8	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. *Multiple Sclerosis Journal*, **2013**, 19, 1074-83	5	72
7	Vitamin A: yet another player in multiple sclerosis pathogenesis?. *Expert Review of Clinical Immunology*, **2013**, 9, 113-5	5.1	4
6	Wallerian and trans-synaptic degeneration contribute to optic radiation damage in multiple sclerosis: a diffusion tensor MRI study. *Multiple Sclerosis Journal*, **2013**, 19, 1610-7	5	49
5	Microstructural magnetic resonance imaging of cortical lesions in multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 418-26	5	31
4	Gray matter damage predicts the accumulation of disability 13 years later in MS. *Neurology*, **2013**, 81, 1759-67	6.5	133

3	Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. *Neurology*, **2012**, 78, 969-75	6.5	90
2	Intrinsic damage to the major white matter tracts in patients with different clinical phenotypes of multiple sclerosis: a voxelwise diffusion-tensor MR study. *Radiology*, **2011**, 260, 541-50	20.5	54
1	Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. *Journal of Neurology*,	5.5	2